Fig 1 - available via license: Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International
Content may be subject to copyright.
Computed tomography (CT) scan of the abdomen showing a 2.5 � 2.0 cm mass in the right ureter, with right hydronephrosis (a) and lithiasis (b). Fig. 2. Mass with grossly negative surgical margins found within the wall of the right ureter (a, b).
Source publication
Small cell carcinoma in the ureter is extremely rare, with few cases reported in the literature. The current report describes the case of a 63-year-old man who presented with right-side back pain. A mass was identified in the right ureter. A nephroureterectomy was performed. Subsequent microscopic examination revealed that the mass comprised a mono...
Context in source publication
Context 1
... and lithiasis ( Fig. 1-a, b). Chest CT was also reviewed, revealing no primary or metastatic lung lesion. We observed no lymphadenopathy in the pelvis, retroperitoneum, or para-aortic region. The patient underwent a right nephroureterectomy. A mass was found within the wall of the right ureter, with grossly negative surgical margins ( Fig. 2-a, b). Microscopic examination showed that the tumor comprised small cells with a round to fusiform shape, scant cytoplasm, finely granular nuclear chromatin, and absent or inconspicuous nucleoli (Fig. 3-a, b). Immunohistochemical staining for the tumor cells was positive for cluster of AE1/AE3 and synaptophysin. The patient was diagnosed ...
Similar publications
Background:
Primary ureteral neoplasia in dogs is extremely rare. To the best of the authors' knowledge, this is the second documented case of a primary ureteral hemangiosarcoma. This case report describes the clinical and pathological findings of a primary distal ureteral hemangiosarcoma.
Case presentation:
A 12-year-old spayed female goldendoo...
Citations
... The median survival ranges from 8.2 months with surgery alone to 24 months with adjuvant platinum-based chemotherapy [111,113,114]. Platinum-based chemotherapy with EP (etoposide and cisplatin) or CE (carboplatin and etoposide) has shown a response rate of 69% [119]. The irinotecan and cisplatin have also been shown to achieve the tumor reduction [111,120]. ...
Primary neuroendocrine neoplasms are a rare heterogeneous group of tumors that include well-differentiated neuroendocrine tumors, poorly differentiated neuroendocrine carcinoma, and paraganglioma. An extensive literature search was used to compile the data regarding epidemiology, pathogenesis, imaging features, and management of the urinary system NENs. We also included the updated staging of the NENs at various locations of the urinary system.
... Platinum-based doublet chemotherapy regimen was recommended in SCC. EP (etoposide and cisplatin) or CE (carboplatin and etoposide) regimen is one of the classic frontline therapies for this tumor, with a response rate of 69% (15). Adjuvant chemotherapy could reduce the risk of early disease progression compared to surgery alone. ...
Background
Primary small cell neuroendocrine carcinoma (SCNEC) in the ureter is extremely rare and has been sporadically reported in case reports. Its incidence, diagnosis, treatment, and outcomes have not yet been thoroughly understood. Here we present a patient with advanced SCNEC in the ureter who was treated by multimodal strategies. To the best of our knowledge, this is the first literature report about the clinical outcomes of the combination of programmed death ligand 1 (PD-L1) immune checkpoint inhibitors (ICIs) and radiotherapy in patient with primary ureteral SCNEC.
Case Presentation
A 71-year old male presented with right flank pain and gross hematuria. A laparoscopic right nephroureterectomy was performed. He was diagnosed with primary ureteral SCNEC, pT3N0M0. Following the surgery, 4 cycles of adjuvant chemotherapy with carboplatin and etoposide (CE) were administered, with disease-free survival (DFS) of 10.1 months. He was then offered 4 cycles of palliative first-line chemotherapy with nedaplatin and irinotecan. The disease was continuously progressed, with progression-free survival (PFS) of 3.7 months. The patient subsequently received second-line treatment with PD-L1 ICI combined with radiotherapy. Unfortunately, hyperprogressive disease was found at the end of treatment. MRI and CT scan showed bilateral pubic bones, right acetabulum, and liver metastases. Without further intervention, the patient died from extensive metastatic disease 2 months after diagnosis, with overall survival (OS) of 18.2 months.
Conclusion
Physicians must be aware of this rare and aggressive carcinoma at its initial presentation. Special attention should be paid to the potential likelihood of hyperprogression during the treatment.
